Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.2% - Time to Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price dropped 5.2% during trading on Wednesday . The stock traded as low as $13.21 and last traded at $12.99. Approximately 306,551 shares changed hands during trading, a decline of 77% from the average daily volume of 1,325,683 shares. The stock had previously closed at $13.70.

Analyst Ratings Changes

CAPR has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 4th. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Stock Performance

The company has a market capitalization of $582.47 million, a PE ratio of -12.08 and a beta of 4.10. The company's 50-day simple moving average is $14.34 and its 200-day simple moving average is $14.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Oppenheimer & Co. Inc. boosted its holdings in shares of Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock valued at $1,040,000 after acquiring an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $161,000. FMR LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $370,000. BNP Paribas Financial Markets boosted its holdings in shares of Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company's stock valued at $269,000 after acquiring an additional 15,872 shares in the last quarter. Finally, Fred Alger Management LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $399,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.